ACC: Esperion's Nexletol busts cholesterol levels regardless of statin, ezitimibe therapy
Esperion notched major back-to-back FDA wins in February with its cholesterol-busting duo Nexlitol and Nexlizet. Now, with physicians largely unfamiliar with the drugs, Esperion is hoping new clinical data will help build confidence as both prepare to hit the market.